导航菜单
On June 15, 2026, China's National Medical Products Administration(NMPA) released two draft mandatory national standards for public consultation: Evaluation Criteria and Management Principles for Cosmetic Cheilitis and Evaluation Criteria and Management Principles for Cosmetic Contact Urticaria. The consultation period runs from June 15 to August 15, 2026.
Since the implementation of the Cosmetic Supervision and Administration Regulation(CSAR) in 2021, China has established a cosmetic adverse reaction monitoring system. The Measures for the Management of Cosmetic Adverse Reaction Monitoring further introduced the principle of “suspected cases should be reported.” However, unified national criteria for determining specific types of adverse reactions have been lacking.
The introduction of these two draft standards serves as a technical supplement to the existing regulatory framework, providing clearer guidance for consumer protection, corporate compliance, and the high-quality development of the cosmetics industry.
ZMUni Insights
How industry stakeholders can prepare for the updated regulatory direction:
Tighten R&D control over high-risk ingredients, ensuring strict compliance with the Cosmetic Safety Technical Standard (STSC); newly monitored ingredients must strictly adhere to registered technical requirements.
Optimize supplier qualification management and ensure complete safety documentation (e.g., MSDS, COA, specifications, safety assessment reports) with robust batch quality control.
Upgrade adverse reaction tracking systems, particularly for lip, fragrance, and high-performance skincare products, while conducting regular post-market risk reviews.
Enhance internal training on adverse reaction identification, severity assessment, and handling procedures, maintaining complete, audit-ready documentation.
Reinforce complaint monitoring mechanisms to enable timely formulation adjustments, proactive risk communication, and swift product recall actions when necessary.
